Oncolytics Biotech Inc. (TSX:ONC)
Canada · Delayed Price · Currency is CAD | Market Cap | 142.51M |
| Revenue (ttm) | n/a |
| Net Income | -30.41M |
| EPS | -0.37 |
| Shares Out | 100.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,627 |
| Open | 1.420 |
| Previous Close | 1.390 |
| Day's Range | 1.390 - 1.440 |
| 52-Week Range | 0.445 - 2.080 |
| Beta | 1.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 1, 2025 |
About Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing... [Read more]
Financial Performance
Financial StatementsNews
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positive FDA Guidance
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positive FDA Guidance
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and...
Oncolytics' Pelareorep Gets Fast Track Designation In Second-Line And Later Anal Cancer; Stock Down
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to Pelareorep in comb...
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third F...
Oncolytics Reports Progress In REO 033 Trial, Plans FDA Meeting Ahead; Shares Jump
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage company, provided a clinical and regulatory update on REO 033, the company's study evaluating Pelareorep in combination for the second-line...
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential ...
Oncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044
(RTTNews) - Oncolytics Biotech Inc. (ONCY) has secured a new U.S. Patent that extends protection over the commercial manufacturing process of its investigational immunotherapy Pelareorep, marking anot...
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional pa...
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically a...
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from ...
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal ca...
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-M...
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient ...
Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Monday announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration FDA on April 1...
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...
Oncolytics Biotech® Completes Domicile Change to the United States
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the...
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS...
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70...
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC , March 3, 2026 /CNW/ --The global oncology market is projected to nearly triple from $279.98 billion in 2026...
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRA...
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Focus on Key Trials
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Focus on Key Trials
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate ma...
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Treatment
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Treatment
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population